Key Details
Price
$41.42Annual Revenue
$370.00 MAnnual EPS
-$1.94Annual ROE
-8.17%Beta
1.77Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day.
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close.
What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years.
CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth.
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.
CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases.
CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In 2024, the biotech sector has not performed as well as the overall market. The SPDR S&P Biotech ETF, which is a key measure for the industry, has increased by 9% this year, while the S&P 500 has risen by 28%. However, both CRISPR Therapeutics and Exelixis still have promising futures despite the different trends.
FAQ
- What is the primary business of CRISPR Therapeutics AG?
- What is the ticker symbol for CRISPR Therapeutics AG?
- Does CRISPR Therapeutics AG pay dividends?
- What sector is CRISPR Therapeutics AG in?
- What industry is CRISPR Therapeutics AG in?
- What country is CRISPR Therapeutics AG based in?
- When did CRISPR Therapeutics AG go public?
- Is CRISPR Therapeutics AG in the S&P 500?
- Is CRISPR Therapeutics AG in the NASDAQ 100?
- Is CRISPR Therapeutics AG in the Dow Jones?
- When was CRISPR Therapeutics AG's last earnings report?
- When does CRISPR Therapeutics AG report earnings?
- Should I buy CRISPR Therapeutics AG stock now?